Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Blonanserin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Sumitomo Dainippon Pharma
- 19 Jul 2017 Status changed from active, no longer recruiting to completed.
- 21 Jul 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jul 2017.
- 08 Jul 2016 Status changed from recruiting to active, no longer recruiting.